Platelet-Rich Plasma Injections as a Treatment for Refractory Patellar Tendinosis: A Meta-Analysis of Randomised Trials
- Author:
Leanne DUPLEY
1
;
Charalambos P. CHARALAMBOUS
Author Information
- Publication Type:Meta-Analysis
- Keywords: Patella; Tendinopathy; Platelet-rich plasma; Injection
- MeSH: Athletes; Follow-Up Studies; Humans; Outcome Assessment (Health Care); Patella; Platelet-Rich Plasma; Sports; Tendinopathy
- From:The Journal of Korean Knee Society 2017;29(3):165-171
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Patellar tendinosis (PT) is a common condition amongst athletes. In this study, we perform a meta-analysis on randomised controlled trials (RCTs) to evaluate the use of platelet-rich plasma (PRP) for refractory PT. METHODS: A literature search was undertaken in various databases from their year of inception to October 2015. The primary outcome measure was the Victorian Institute of Sports Assessment-Patella (VISA-P) score. RESULTS: We identified 2 RCTs comparing PRP injections to alternative treatment options (extracorporeal shockwave therapy [ESWT] and dry needling of the tendon). Meta-analysis showed no significant difference in mean VISA-P scores between PRP injection and control at early assessment (2 or 3 months; estimated difference in means, 11.9; standard error [SE], 7.4; 95% confidence interval [CI], −2.7 to 26.4; p=0.109). However, PRP was statistically better than control with regards to VISA-P scores at longer follow-up (6 months or longer; estimated difference in means, 12.7; SE, 4.4; 95% CI, 4.1 to 21.3; p=0.004). CONCLUSIONS: There is a paucity of RCTs evaluating the role of PRP in PT. Our results suggest that, based on limited evidence, PRP is superior over other established non-surgical treatments (dry needling and ESWT) for refractory PT. Larger RCTs may allow better characterisation of the role of PRP in this condition.
